Small cell lung cancer vaccine - MabVax/MSKCC

Drug Profile

Small cell lung cancer vaccine - MabVax/MSKCC

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Memorial Sloan-Kettering Cancer Center
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Small cell lung cancer

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Small-cell-lung-cancer(Second-line therapy or greater) in USA (SC, Injection)
  • 08 Jul 2014 MabVax Therapeutics merged with a wholly-owned subsidiary of Telik
  • 31 May 2011 Phase-I clinical trials in Small cell lung cancer in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top